MedTrace Logo

The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients

NCT01186471 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-03-20

No results posted yet for this study

Summary

This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.

Conditions

Interventions

OTHER

A643 (nicotine)

1mg oromucosal nicotine spray- three times daily during each treatment period

OTHER

A643 (nicotine)

2mg oromucosal nicotine spray- three times daily during each treatment period

DRUG

placebo

placebo - three times daily during each treatment period

Sponsors & Collaborators

  • Agentschap voor Innovatie door Wetenschap en Technologie

    collaborator OTHER

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutica N.V. Clinical Trial · Janssen Pharmaceutica N.V.

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Completion
2011-03-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01186471 on ClinicalTrials.gov